| Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH (NCT06677788) | Tanta University | 2022-04-01 |
| Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant (NCT05553470) | Corcept Therapeutics | 2022-03-03 |
| Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH) (NCT05423327) | Regeneron Pharmaceuticals | 2021-12-09 |
| Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis (NCT04880187) | Axcella Health, Inc | 2021-05-07 |
| A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) (NCT04820036) | Brigham and Women's Hospital | 2021-05-06 |
| A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) (NCT04771273) | Boehringer Ingelheim | 2021-04-27 |
| Combined Active Treatment in Type 2 Diabetes With NASH (NCT04639414) | German Diabetes Center | 2021-03-26 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis (NCT04607655) | Galecto Biotech AB | 2021-03-01 |
| A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (NCT04483947) | AstraZeneca | 2020-11-06 |
| The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF (NCT04682600) | Sonic Incytes | 2020-10-21 |
| A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects (NCT04481594) | Hepanova Inc. | 2020-09-08 |
| Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH) (NCT04140123) | Guangdong Raynovent Biotech Co., Ltd | 2020-06-23 |
| Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH (NCT04060368) | Instituto de Investigación Marqués de Valdecilla | 2020-06-01 |
| Endoscopic Bariatric Therapy in NASH Cirrhosis (NCT04281303) | Instituto de Investigación Marqués de Valdecilla | 2020-04-01 |
| Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (NCT04065841) | Novartis Pharmaceuticals | 2019-12-30 |
| Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis (NCT05050721) | Methodist Health System | 2019-10-04 |
| A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. (NCT04019561) | MedImmune LLC | 2019-09-23 |
| A Phase 2b Study of Icosabutate in Fatty Liver Disease (NCT04052516) | NorthSea Therapeutics B.V. | 2019-07-17 |
| A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) (NCT02653300) | Oramed, Ltd. | 2018-09-20 |
| Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis (NCT03517540) | Novartis Pharmaceuticals | 2018-09-11 |
| A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NCT02927314) | Can-Fite BioPharma | 2017-11-27 |
| Longitudinal Observational Study Of Chinese With NAFLD/NASH (NCT03151473) | Humanity and Health Research Centre | 2017-05-08 |
| Phase 2b Study in NASH to Assess IVA337 (NCT03008070) | Inventiva Pharma | 2017-02-07 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH (NCT02913105) | Novartis Pharmaceuticals | 2016-10-24 |
| Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (NCT02855164) | Novartis Pharmaceuticals | 2016-08-01 |
| Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study (NCT02754037) | University of California, Davis | 2016-04-30 |
| A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (NCT02612662) | AstraZeneca | 2015-11-24 |
| Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD) (NCT02605616) | University of Alabama at Birmingham | 2015-11-01 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (NCT02548351) | Intercept Pharmaceuticals | 2015-09-22 |
| Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 (NCT02466516) | Gilead Sciences | 2015-06-08 |
| A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis (NCT02316717) | Immuron Ltd. | 2014-12-01 |
| Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults (NCT02654665) | Changi General Hospital | 2014-03-01 |
| DHA and Vitamin D in Children With Biopsy-proven NAFLD (NCT02098317) | Bambino Gesù Hospital and Research Institute | 2014-01-01 |
| Gut Microbiota and Modulation of Liver Damage in NAFLD (NCT02158351) | University of Roma La Sapienza | 2013-11-01 |
| Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis (NCT01950884) | University of Palermo | 2013-10-01 |
| Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis (NCT01899859) | Galectin Therapeutics Inc. | 2013-07-01 |
| Blood Collection Biorepository for Liver Disease Research (NCT03025074) | State University of New York at Buffalo | 2013-07-01 |
| Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease (NCT01894438) | Harokopio University | 2013-04-01 |
| Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D (NCT01571063) | University of Zurich | 2013-01-01 |
| Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH (NCT00706537) | Pfizer | 2008-07-01 |